Preliminary Metabolomics Data Reveals Lipid Metabolism and Oxidative Stress Metabolites as Potential Biomarkers for Patent Ductus Arteriosus
Biomedical Chromatography · 2025
DOI: 10.1002/bmc.70125 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Mustafa Çelebier und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Department of Analytical Chemistry, Hacettepe University, Ankara, Turkey. Hauptthemen laut MEDLINE: Ductus Arteriosus, Patent, Biomarkers, Metabolomics, Oxidative Stress. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Hacettepe University Faculty of Pharmacy-HUNİKAL Laboratory.
Abstract (Originalsprache)
Patent ductus arteriosus (PDA) is a common congenital heart defect in preterm infants and is associated with significant morbidity. Early diagnosis is crucial but challenging due to nonspecific clinical symptoms. This study aims to identify potential metabolomic biomarkers for early detection of PDA using human cord blood. A prospective cross‐sectional study was conducted involving 45 preterm infants between 23 0/6 and 31 6/7 weeks of gestation. The diagnosis of hemodynamically significant PDA (hsPDA) was based on echocardiographic findings after 48 h, showing a left atrium‐to‐aortic root ratio > 1.5 and/or a ductus diameter > 1.5 mm. Untargeted metabolomics analysis was performed on cord blood plasma samples using quadrupole time‐of‐flight liquid chromatography‐mass spectrometry (Q‐TOF LC/MS). Data were processed for metabolites that differed between groups. Twenty infants with hsPDA formed the study group, 25 controls. Out of 4237 detected peaks, 40 showed statistically significant differences (fold change > 1.5, p < 0.05). Among these, 15 metabolites were potentially clinically relevant. Key findings included decreased levels of guanidino acetic acid, S ‐adenosylmethionine, and ceramides and increased levels of docosahexaenoic acid, arachidonic acid, and cholesterol‐related molecules in the PDA group. The study reveals significant metabolic alterations in lipid metabolism and oxidative stress‐related pathways in PDA infants. Further targeted metabolomics studies are warranted to validate and explore clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy, Department of Analytical Chemistry, Hacettepe University, Ankara, Turkey.
- Division of Neonatology, University of Health Sciences, Ankara Bilkent City Hospital, Ankara, Turkey.
- Faculty of Pharmacy, Department of Analytical Chemistry, Başkent University, Ankara, Turkey.
- Department of Pediatric Cardiology, University of Health Sciences, Ankara Bilkent City Hospital, Ankara, Turkey.
- Department of Obstetrics and Gynecology, University of Health Sciences, Ankara Bilkent City Hospital, Ankara, Turkey.
ORCID-Profile: Mustafa Çelebier, Evrim Alyamac Dizdar
Förderung
- Hacettepe University Faculty of Pharmacy-HUNİKAL Laboratory
Zitieren
APA
Çelebier, M., Yazici, A., Eneş, D., Kurt, A., Fidan, B. B., Cetin, I. I., Sahin, D., Dizdar, E. A., & Sari, F. N. (2025). Preliminary Metabolomics Data Reveals Lipid Metabolism and Oxidative Stress Metabolites as Potential Biomarkers for Patent Ductus Arteriosus. Biomedical Chromatography. https://doi.org/10.1002/bmc.70125
Vancouver
Çelebier M, Yazici A, Eneş D, Kurt A, Fidan BB, Cetin II, et al. Preliminary Metabolomics Data Reveals Lipid Metabolism and Oxidative Stress Metabolites as Potential Biomarkers for Patent Ductus Arteriosus. Biomedical Chromatography. 2025. doi:10.1002/bmc.70125
BibTeX
@article{elebier2025,
author = {Çelebier, Mustafa and Yazici, Aybuke and Eneş, Duygu and Kurt, Abdullah and Fidan, Bilge Başak and Cetin, Ibrahim Ilker and Sahin, Dilek and Dizdar, Evrim Alyamac and Sari, Fatma Nur},
title = {Preliminary Metabolomics Data Reveals Lipid Metabolism and Oxidative Stress Metabolites as Potential Biomarkers for Patent Ductus Arteriosus},
journal = {Biomedical Chromatography},
year = {2025},
doi = {10.1002/bmc.70125}
}
EUVIMED